ArticleClinical pharmacology : advances and applications2014

Glibenclamide in patients with poorly controlled type 2 diabetes: a 12-week, prospective, single-center, open-label, dose-escalation study.

Virendra Rambiritch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.